AU016757; Avian myelocytomatosis viral oncogene homolog; bHLHe39; c Myc; Class E basic helix-loop-helix protein 39; MRTL; Myc; Myc protein; Myc proto oncogene protein; Myc proto-oncogene protein; myc-related translation/localization regulatory factor; MYC_HUMAN; Myc2; MYCC; Myelocytomatosis oncogene; Niard; Nird; Oncogene Myc; OTTHUMP00000158589; Proto-oncogene c-Myc; Protooncogene homologous to myelocytomatosis virus; RNCMYC; Transcription factor p64; Transcriptional regulator Myc-A; V-Myc avian myelocytomatosis viral oncogene homolog; v-myc myelocytomatosis viral oncogene homolog (avian);
WB: 1:500-1:3000, IHC: 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
Human, Mouse, Rat
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
Rabbit
Polyclonal
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
c-Myc Antibody detects endogenous levels of total c-Myc.
AB_2833523
Please cite this product as: Affinity Biosciences Cat# AF0358, RRID:AB_2833523.
Liquid
1mg/ml
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt.
A synthesized peptide derived from human c-Myc, corresponding to a region within N-terminal amino acids.
>>Visit The Human Protein Atlas
MYC
Observed Mol.Wt.: 49kD.
Predicted Mol.Wt.: 49kDa(Calculated)..
Nucleus > nucleoplasm. Nucleus > nucleolus.
Myc a proto-oncogenic transcription factor that plays a role in cell proliferation, apoptosis and in the development of human tumors.. Seems to activate the transcription of growth-related genes.
MPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells. Functions with TAF6L to activate target gene expression through RNA polymerase II pause release (By similarity).
Phosphorylated by PRKDC. Phosphorylation at Ser-329 by PIM2 leads to the stabilization of MYC (By similarity). Phosphorylation at Ser-62 by CDK2 prevents Ras-induced senescence. Phosphorylated at Ser-62 by DYRK2; this primes the protein for subsequent phosphorylation by GSK3B at Thr-58. Phosphorylation at Thr-58 and Ser-62 by GSK3 is required for ubiquitination and degradation by the proteasome.
Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-58 and Ser-62, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28 but by USP36, due to the lack of interaction between isoform 3 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex. Ubiquitinated by TRIM6 in a phosphorylation-independent manner (By similarity).
Nucleus>Nucleoplasm. Nucleus>Nucleolus.
Efficient DNA binding requires dimerization with another bHLH protein. Binds DNA as a heterodimer with MAX. Interacts with TAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A and KDM5B. Interacts (when phosphorylated at Thr-58 and Ser-62) with FBXW7. Interacts with PIM2. Interacts with RIOX1. The heterodimer MYC:MAX interacts with ABI1; the interaction may enhance MYC:MAX transcriptional activity. Interacts with TRIM6 (By similarity). Interacts with NPM1; the binary complex is recruited to the promoter of MYC target genes and enhances their transcription. Interacts with CIP2A; leading to the stabilization of MYC.
· Cellular Processes > Cell growth and death > Cellular senescence.(View pathway)
· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.(View pathway)
· Cellular Processes > Cell growth and death > Cell cycle.(View pathway)
· Environmental Information Processing > Signal transduction > Hippo signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > MAPK signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > Wnt signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > ErbB signaling pathway.(View pathway)
· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.
· Human Diseases > Infectious diseases: Viral > HTLV-I infection.
· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.
· Human Diseases > Infectious diseases: Viral > Hepatitis B.
· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Small cell lung cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.(View pathway)
· Human Diseases > Cancers: Specific types > Breast cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Endometrial cancer.(View pathway)
· Human Diseases > Cancers: Overview > MicroRNAs in cancer.
· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.(View pathway)
· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.(View pathway)
· Human Diseases > Cancers: Overview > Proteoglycans in cancer.
· Human Diseases > Cancers: Specific types > Colorectal cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Gastric cancer.(View pathway)
· Human Diseases > Cancers: Overview > Pathways in cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Bladder cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Thyroid cancer.(View pathway)
· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.(View pathway)
AF0358-BP
(Blocking peptide available as AF0358-BP)
$350/1mg.
Tips: For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
This product is for research use only. Not for use in diagnostic or therapeutic procedures.
Site | PTM Type | Enzyme | Source |
---|---|---|---|
Ubiquitination | Uniprot | ||
S6 | Phosphorylation | Uniprot | |
T8 | Phosphorylation | P04049 (RAF1) | Uniprot |
Y12 | Phosphorylation | Uniprot | |
Y16 | Phosphorylation | Uniprot | |
Y22 | Phosphorylation | Uniprot | |
Y32 | Phosphorylation | P00519 (ABL1) | Uniprot |
K51 | Sumoylation | Uniprot | |
K51 | Ubiquitination | Uniprot | |
K52 | Sumoylation | Uniprot | |
K52 | Ubiquitination | Uniprot | |
T58 | O-Glycosylation | Uniprot | |
T58 | Phosphorylation | P49841 (GSK3B) , P28482 (MAPK1) , P49840 (GSK3A) , P53779 (MAPK10) , P45983 (MAPK8) | Uniprot |
S62 | Phosphorylation | Q13627 (DYRK1A) , P45984 (MAPK9) , Q00535 (CDK5) , P28482 (MAPK1) , P45983 (MAPK8) , Q92630 (DYRK2) , P53779 (MAPK10) , P42345 (MTOR) | Uniprot |
S64 | Phosphorylation | Uniprot | |
S67 | Phosphorylation | Uniprot | |
S71 | Phosphorylation | P28482 (MAPK1) , P45984 (MAPK9) , P53779 (MAPK10) , P45983 (MAPK8) | Uniprot |
Y74 | Phosphorylation | P00519 (ABL1) | Uniprot |
T78 | Phosphorylation | Uniprot | |
S81 | Phosphorylation | Uniprot | |
K143 | Acetylation | Uniprot | |
K148 | Acetylation | Uniprot | |
K148 | Sumoylation | Uniprot | |
K148 | Ubiquitination | Uniprot | |
S151 | Phosphorylation | Uniprot | |
K157 | Acetylation | Uniprot | |
K157 | Sumoylation | Uniprot | |
K157 | Ubiquitination | Uniprot | |
S161 | Phosphorylation | Uniprot | |
T244 | Phosphorylation | Uniprot | |
S249 | Phosphorylation | P68400 (CSNK2A1) | Uniprot |
S250 | Phosphorylation | P68400 (CSNK2A1) | Uniprot |
S252 | Phosphorylation | P68400 (CSNK2A1) , P48729 (CSNK1A1) | Uniprot |
K275 | Acetylation | Uniprot | |
S277 | Phosphorylation | Uniprot | |
S279 | Phosphorylation | Uniprot | |
S281 | Phosphorylation | Uniprot | |
S288 | Phosphorylation | Uniprot | |
K289 | Ubiquitination | Uniprot | |
S293 | Phosphorylation | Uniprot | |
K298 | Ubiquitination | Uniprot | |
K317 | Acetylation | Uniprot | |
K317 | Sumoylation | Uniprot | |
K323 | Acetylation | Uniprot | |
K323 | Sumoylation | Uniprot | |
K323 | Ubiquitination | Uniprot | |
K326 | Sumoylation | Uniprot | |
K326 | Ubiquitination | Uniprot | |
S329 | Phosphorylation | P11309 (PIM1) , Q9P1W9 (PIM2) | Uniprot |
S337 | Phosphorylation | Uniprot | |
T343 | Phosphorylation | Uniprot | |
S344 | Phosphorylation | Uniprot | |
S347 | Phosphorylation | P68400 (CSNK2A1) | Uniprot |
S348 | Phosphorylation | P68400 (CSNK2A1) | Uniprot |
T350 | Phosphorylation | Uniprot | |
K355 | Sumoylation | Uniprot | |
K355 | Ubiquitination | Uniprot | |
T358 | Phosphorylation | Q13177 (PAK2) | Uniprot |
K371 | Acetylation | Uniprot | |
S373 | Phosphorylation | Q13177 (PAK2) | Uniprot |
K389 | Sumoylation | Uniprot | |
K389 | Ubiquitination | Uniprot | |
K392 | Sumoylation | Uniprot | |
K392 | Ubiquitination | Uniprot | |
K398 | Sumoylation | Uniprot | |
K398 | Ubiquitination | Uniprot | |
T400 | Phosphorylation | Q13177 (PAK2) | Uniprot |
S405 | Phosphorylation | Uniprot | |
K412 | Sumoylation | Uniprot | |
K412 | Ubiquitination | Uniprot | |
K422 | Ubiquitination | Uniprot | |
K430 | Sumoylation | Uniprot | |
K430 | Ubiquitination | Uniprot |